Authors
Latest:
Successful treatment of bilateral diffuse Uveal melanocytic proliueration with plasmapheresisNonetheless,BDUMP remains a rare condition with fewer than 60 cases documented in literature.
Latest:
Key Takeaways on Managing Neovascular AMD and DMENathan Steinle, MD; Adrienne Scott, MD; Carl Regillo, MD, FACS, FASRS; and Prethy Rao, MD, MPH, share final thoughts on the changing treatment landscape of neovascular AMD and DME.
Latest:
Leaders in academic ophthalmology discuss AI for eye screeningArtificial intelligence in a primary care and clinic settings increases the likelihood of catching diabetic retinopathy in underinsured patients, resulting in increased successful referrals.
Latest:
Pearls for managing diabetic retinopathy in pediatric patientsInsulin pumps, digital technology and outcome analyses are useful tools
Latest:
Serious adverse reaction halts gene therapy for diabetic macular edemaDespite setbacks in DME, Adverum Biotechnologies said it will continue to develop ADVM-022 for wet AMD.
Latest:
Ultra-widefield imaging: A critical step in uveitis diagnosis and managementA multifaceted evaluation that includes ultra-widefield imaging can reveal new information and influence treatment decisions.
Latest:
Key Takeaways on Managing Neovascular AMD and DMENathan Steinle, MD; Adrienne Scott, MD; Carl Regillo, MD, FACS, FASRS; and Prethy Rao, MD, MPH, share final thoughts on the changing treatment landscape of neovascular AMD and DME.
Latest:
Learnings from Real World Evidence of Faricimab in nAMD and DME: Part 2Arshad M. Khanani, MD, MA, FASRS, highlights the fluid resolution with faricimab and the need for loading doses, especially in high-needs switch patients with nAMD or DME.
Latest:
The current state of gene therapy in managing neovascular macular degenerationGene therapy offers a promising alternative by potentially providing long-lasting effects from a single treatment.
Latest:
A-memia? Anecdotal evidence in the era of memesIan C. Han, MD, shares his thoughts on the value of anecdotal evidence in our winter 2024 editorial.
Latest:
Intravitreal pegcetacoplan for retinal tissue preservation in patients with GAGarg reported the 30-month data showing that patients receiving pegcetacoplan experienced an increasing treatment effect compared with sham (ie, a decrease in GA lesion area over time).
Latest:
Case 2: Treatment-Experienced nAMD Switch to Aflibercept 8mgDavid Eichenbaum, MD, FASRS concludes this series with the final case of a treatment-experienced patient switching from aflibercept 2 mg to high-dose aflibercept 8 mg with noticeable improvement after the first dose.
Latest:
How ophthalmology is pioneering the field of artificial intelligenceRetinal imaging tests are providing material to train and test decision support systems.
Latest:
Pediatric ophthalmologists target inherited retinal diseasesNew opportunities continue to develop in an evolving landscape.
Latest:
Case series finds floaters are a common side effect of SyfovreThe authors of a case series say silicone oil droplets from silicone used to lubricate the McKesson syringes is the most likely cause of the droplets presumed to cause the floaters.
Latest:
Implementing Higher Molar Dose in Your Clinical PracticeJohn Kitchens, MD, and Peter Kaiser, MD, discuss drug duration, accelerating dosing intervals, and other pearls for aflibercept dosing in wet AMD.
Latest:
Optimizing Care For Patients With Retinal DisordersKey takeaways from a discussion on the management of age-related macular degeneration, diabetic macular edema, and inherited retinal disease and insight regarding what to look forward to as the field advances.
Latest:
Key Takeaways on Managing Neovascular AMD and DMENathan Steinle, MD; Adrienne Scott, MD; Carl Regillo, MD, FACS, FASRS; and Prethy Rao, MD, MPH, share final thoughts on the changing treatment landscape of neovascular AMD and DME.
Latest:
Office vitrectomy: A full-scale replacement for the ASC and hospitalWe stand on the cusp of a new era in vitreoretinal surgery, one that has been marked by only a select few seminal innovations
Latest:
Advancements in ocular drug deliveryOptions empower patients and providers to decrease treatment burden
Latest:
OCT: First 2D image by Adolf Fercher paved the way for today’s imaging techniqueIn the 30 years since optical coherence tomography was first described, it has become one of the most widely used technologies for imaging the human eye.
Latest:
Listening to the heart: Lessons from cardiology in remote monitoring and AIRather than speculating in a vacuum about the future of remote monitoring in ophthalmology, it is better to explore how other specialties in medicine adopted and integrated remote monitoring into their care plan frameworks.
Latest:
Dexamethasone rebuttal: Who should perform intravitreal injections?In response to a previously published article, three ophthalmologists present their views on intravitreal pharmacotherapy injections.
Latest:
OCT: First 2D image by Adolf Fercher paved the way for today’s imaging techniqueIn the 30 years since optical coherence tomography was first described, it has become one of the most widely used technologies for imaging the human eye.
